sorafenib has been researched along with stilbenes in 4 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (stilbenes) | Trials (stilbenes) | Recent Studies (post-2010) (stilbenes) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 13,935 | 245 | 7,836 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, KS; Baek, SH; Kim, C; Shim, BS; Um, JY | 1 |
| Bennett, LL; Mondal, A | 1 |
| Chen, X; Liu, Y; Liu, Z; Ma, S; Sakurai, K; Song, W; Tang, Z; Wang, G; Wang, Y; Yu, H; Zhang, D | 1 |
| Chen, J; He, ML; Huo, X; Wang, C; Zhao, T | 1 |
4 other study(ies) available for sorafenib and stilbenes
| Article | Year |
|---|---|
Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPĪµ and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Survival; Humans; Kidney Neoplasms; Membrane Potential, Mitochondrial; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Receptor-Like Protein Tyrosine Phosphatases, Class 4; Resveratrol; S Phase Cell Cycle Checkpoints; Signal Transduction; Sorafenib; STAT3 Transcription Factor; STAT5 Transcription Factor; Stilbenes | 2016 |
Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caspase 3; Cell Cycle Checkpoints; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Humans; MCF-7 Cells; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Resveratrol; Sorafenib; Stilbenes; Treatment Outcome | 2016 |
Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Survival; Human Umbilical Vein Endothelial Cells; Humans; Ki-67 Antigen; Liver Neoplasms; Male; Mice, Inbred BALB C; Nanoparticles; Platelet Endothelial Cell Adhesion Molecule-1; Sorafenib; Stilbenes; Treatment Outcome; Vascular Endothelial Growth Factor A | 2019 |
Pterostilbene enhances sorafenib's anticancer effects on gastric adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Death; Cell Line, Tumor; Cell Shape; Cell Survival; Drug Synergism; G1 Phase Cell Cycle Checkpoints; Male; Mice, Inbred BALB C; Mice, Nude; Sorafenib; Stilbenes; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2020 |